Analyst Estimates: Here's What Brokers Think Of Halozyme Therapeutics, Inc. (NASDAQ:HALO) After Its Full-Year Report [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
Halozyme Therapeutics reported in line with analyst predictions, delivering revenues of US$829m and statutory earnings per share of US$2.10, suggesting the business is executing well and in line with its plan. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year. Check out our latest analysis for Halozyme Therapeutics Following the latest results, Halozyme Therapeutics' ten analysts are now forecasting revenues of US$956.8m in 2024. This would be a decent 15% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to jump 35% to US$2.99. Before this earnings report, the analysts had been forecasting revenues of US$961.1m and earnings per share (EPS) of US$3.00 in 2024. The conse
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- How Novo-Catalent Deal Affects Halozyme (HALO)? [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.MarketBeat
- Mahesh Krishnan Elected to Halozyme's Board of Directors [Yahoo! Finance]Yahoo! Finance
- Mahesh Krishnan Elected to Halozyme's Board of DirectorsPR Newswire
- Why This 1 Value Stock Could Be a Great Addition to Your Portfolio [Yahoo! Finance]Yahoo! Finance
HALO
Earnings
- 2/20/24 - Beat
HALO
Sec Filings
- 4/29/24 - Form 4
- 4/29/24 - Form 4
- 4/29/24 - Form 4
- HALO's page on the SEC website